Study of Efficacy and Safety of Privigen in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy

PHASE3CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

November 30, 2010

Primary Completion Date

November 30, 2011

Study Completion Date

November 30, 2011

Conditions
Chronic Inflammatory Demyelinating Polyneuropathy
Interventions
BIOLOGICAL

10% liquid formulation of human immunoglobulin

Trial Locations (22)

Unknown

Study Site, Brussels

Study Site, Edegem

Study Site, Ghent

Study Site, Leuven

Study Site, Helsinki

Study Site, Turku

Study Site, Vaasa

Study Site, Limoges

Study Site, Lyon

Study Site, Marseille

Study Site, Montpellier

Study Site, Paris

Study Site, Berlin

Study Site, Feldberger Seenlandschaft

Study Site, Göttingen

Study Site, Itzehoe

Study Site, Prien am Chiemsee

Study Site, Schwedt

Study Site, Würzburg

Study Site, Krakow

Study Site, Lublin

Study Site, Wroclaw

Sponsors

Lead Sponsor

All Listed Sponsors
lead

CSL Behring

INDUSTRY